Search results for "Clin oncol"

showing 1 items of 1 documents

Identification of a genetic signature enriching for response to ibrutinib in relapsed/refractory follicular lymphoma in the DAWN phase 2 trial.

2021

Abstract Background The single‐arm DAWN trial (NCT01779791) of ibrutinib monotherapy in patients with relapsed/refractory follicular lymphoma (FL) showed an overall response rate (ORR) of 20.9% and a median response duration of 19.4 months. This biomarker analysis of the DAWN dataset sought to determine genetic classifiers for prediction of response to ibrutinib treatment. Methods Whole exome sequencing was performed on baseline tumor samples. Potential germline variants were excluded; a custom set of 1216 cancer‐related genes was examined. Responder‐ versus nonresponder‐associated variants were identified using Fisher's exact test. Classifiers with increasing numbers of genes were created …

OncologyCancer ResearchFollicular lymphomaBiochemistrychemistry.chemical_compoundGenetic signaturePiperidinesRecurrenceMedicineExomeLymphoma FollicularExome sequencingRC254-282Research ArticlesNeoplasms. Tumors. Oncology. Including cancer and carcinogensHematologyDNA-Binding ProteinsExact testOncologyIbrutinibRefractory Follicular LymphomaClin oncolResearch ArticleGenetic Markersmedicine.medical_specialtyImmunologyAntineoplastic AgentslymphomaBiologyGermline mutationInternal medicinePartial responseExome SequencingHumansRadiology Nuclear Medicine and imagingIn patientbusiness.industryAdeninegenetic variantsClinical Cancer ResearchbiomarkersCell Biologymedicine.diseasemutationsFANCAMutational analysisCARD Signaling Adaptor ProteinschemistryGuanylate CyclaseFamily medicineRelapsed refractoryMutationbusinessCancer medicine
researchProduct